We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down
Read MoreHide Full Article
Key Takeaways
MYGN reported Q4 adjusted EPS of 4 cents, beating estimates by 350% as shares surged 21.7% after hours.
MYGN's revenues of $209.8M topped estimates, driven by gains in cancer and tumor profiling tests.
MYGN's gross margin fell to 70%, while 2026 revenue guidance stands at $860M-$880M.
Myriad Genetics, Inc. (MYGN - Free Report) reported fourth-quarter 2025 adjusted earnings of 4 cents per share, which surpassed the Zacks Consensus Estimate by 350% and increased 33.3% year over year.
Adjusted earnings exclude amortization expenses from acquired intangible assets, equity compensation and real estate optimization. GAAP loss per share came in at 8 cents in the quarter compared with the prior-year quarter’s loss of 47 cents.
For the full year, adjusted earnings were 6 cents per share compared with the year-ago period’s earnings of 14 cents. The Zacks Consensus Estimate projected the company’s 2025 earnings per share (EPS) to be flat.
MYGN’s Revenues
Total revenues fell 0.4% year over year to $209.8 million but exceeded the Zacks Consensus Estimate by 1.07%. Testing volumes increased 2% year over year.
For full-year 2025, revenues totaled $824.5 million, declining 1.6% from the year-ago period. The figure topped the Zacks Consensus Estimate slightly by 0.3%.
Following the announcement yesterday, shares of MYGN jumped 21.7% in the after-hours session.
Detailed Breakdown of MYGN’s Q4 Revenues
In the fourth quarter, Hereditary Cancer testing revenues increased 3% year over year to $96.8 million. Tumor Profiling testing revenues rose 2% year over year to $31.5 million. Prenatal testing revenues came in flat at $44.9 million, while Mental Health revenues decreased 10% to $36.6 million.
Myriad Genetics, Inc. Price, Consensus and EPS Surprise
The gross margin fell 168 basis points (bps) to 70% due to a 5.5% increase in the cost of revenues.
Research and development expenses dropped 14.1% year over year to $25.5 million. SG&A expenses dipped 16.4% to $55.6 million in the reported quarter.
The adjusted operating loss was $3 million compared with a loss of $17.3 million in the year-ago quarter.
MYGN’s Financial Position
Myriad Genetics exited the fourth quarter of 2025 with cash and cash equivalents of $149.6 million compared with $102.4 million at the end of the fourth quarter of 2024.
Long-term debt amounted to $119.9 million, higher than $39.6 million at the end of the fourth quarter of 2024.
The cumulative net cash outflow from operating activities at the end of the reported quarter was $1.8 million compared with an outflow of $8.7 million in the year-ago period.
Myriad Genetics’ 2026 Guidance
Myriad Genetics reiterated its full-year 2026 guidance, which it introduced during preliminary fourth-quarter 2025 results in January. Revenues are expected to be between $860 million and $880 million in 2026. The Zacks Consensus Estimate is pegged at $867.5 million.
Full-year adjusted gross margin is expected to be in the 68%-69% range. Adjusted EBITDA is forecasted in the $37-$49 million band.
Our Take on MYGN
Myriad Genetics exited the fourth quarter of 2025 with better-than-expected earnings and revenues. The company generated strong test volume growth in hereditary cancer testing, which reflects continued momentum in the unaffected market. MYGN is making strong progress in its cancer care continuum strategy to maintain leadership in hereditary cancer testing while expanding into other attractive cancer testing applications. The newly launched expanded MyRisk panel has been well-received in the market. The company is also in the final preparation mode to start commercial testing of PRECISE MRD for breast cancer for a select set of customers.
However, the contraction of gross margin in the quarter is discouraging. Within Mental Health, quarterly revenues were once again impacted by UnitedHealthcare's coverage policy change in January 2025.
MYGN’s Zacks Rank & Key Picks
Myriad Genetics currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Cardinal Health (CAH - Free Report) and Align Technology (ALGN - Free Report) .
Intuitive Surgical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $2.53, which surpassed the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 12.7% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 13.24%.
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter fiscal 2026 adjusted EPS of $2.63, exceeding the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion topped the Zacks Consensus Estimate by 0.9%.
CAH has a long-term earnings growth rate of 15% compared with the industry’s 9.6% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 9.3%.
Align Technology, carrying a Zacks Rank #2 at present, posted a fourth-quarter 2025 adjusted EPS of $3.29, exceeding the Zacks Consensus Estimate by 10.1%. Revenues of $1.05 billion outperformed the Zacks Consensus Estimate by 5.3%.
ALGN has an estimated long-term earnings growth rate of 10.1% compared with the industry’s 9.5% growth. The company’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 6.16%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
MYGN Stock Up on Q4 Earnings and Revenue Beat, Gross Margin Down
Key Takeaways
Myriad Genetics, Inc. (MYGN - Free Report) reported fourth-quarter 2025 adjusted earnings of 4 cents per share, which surpassed the Zacks Consensus Estimate by 350% and increased 33.3% year over year.
Adjusted earnings exclude amortization expenses from acquired intangible assets, equity compensation and real estate optimization. GAAP loss per share came in at 8 cents in the quarter compared with the prior-year quarter’s loss of 47 cents.
For the full year, adjusted earnings were 6 cents per share compared with the year-ago period’s earnings of 14 cents. The Zacks Consensus Estimate projected the company’s 2025 earnings per share (EPS) to be flat.
MYGN’s Revenues
Total revenues fell 0.4% year over year to $209.8 million but exceeded the Zacks Consensus Estimate by 1.07%. Testing volumes increased 2% year over year.
For full-year 2025, revenues totaled $824.5 million, declining 1.6% from the year-ago period. The figure topped the Zacks Consensus Estimate slightly by 0.3%.
Following the announcement yesterday, shares of MYGN jumped 21.7% in the after-hours session.
Detailed Breakdown of MYGN’s Q4 Revenues
In the fourth quarter, Hereditary Cancer testing revenues increased 3% year over year to $96.8 million. Tumor Profiling testing revenues rose 2% year over year to $31.5 million. Prenatal testing revenues came in flat at $44.9 million, while Mental Health revenues decreased 10% to $36.6 million.
Myriad Genetics, Inc. Price, Consensus and EPS Surprise
Myriad Genetics, Inc. price-consensus-eps-surprise-chart | Myriad Genetics, Inc. Quote
MYGN’s Q4 Margin Performance
The gross margin fell 168 basis points (bps) to 70% due to a 5.5% increase in the cost of revenues.
Research and development expenses dropped 14.1% year over year to $25.5 million. SG&A expenses dipped 16.4% to $55.6 million in the reported quarter.
The adjusted operating loss was $3 million compared with a loss of $17.3 million in the year-ago quarter.
MYGN’s Financial Position
Myriad Genetics exited the fourth quarter of 2025 with cash and cash equivalents of $149.6 million compared with $102.4 million at the end of the fourth quarter of 2024.
Long-term debt amounted to $119.9 million, higher than $39.6 million at the end of the fourth quarter of 2024.
The cumulative net cash outflow from operating activities at the end of the reported quarter was $1.8 million compared with an outflow of $8.7 million in the year-ago period.
Myriad Genetics’ 2026 Guidance
Myriad Genetics reiterated its full-year 2026 guidance, which it introduced during preliminary fourth-quarter 2025 results in January. Revenues are expected to be between $860 million and $880 million in 2026. The Zacks Consensus Estimate is pegged at $867.5 million.
Full-year adjusted gross margin is expected to be in the 68%-69% range. Adjusted EBITDA is forecasted in the $37-$49 million band.
Our Take on MYGN
Myriad Genetics exited the fourth quarter of 2025 with better-than-expected earnings and revenues. The company generated strong test volume growth in hereditary cancer testing, which reflects continued momentum in the unaffected market. MYGN is making strong progress in its cancer care continuum strategy to maintain leadership in hereditary cancer testing while expanding into other attractive cancer testing applications. The newly launched expanded MyRisk panel has been well-received in the market. The company is also in the final preparation mode to start commercial testing of PRECISE MRD for breast cancer for a select set of customers.
However, the contraction of gross margin in the quarter is discouraging. Within Mental Health, quarterly revenues were once again impacted by UnitedHealthcare's coverage policy change in January 2025.
MYGN’s Zacks Rank & Key Picks
Myriad Genetics currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Intuitive Surgical (ISRG - Free Report) , Cardinal Health (CAH - Free Report) and Align Technology (ALGN - Free Report) .
Intuitive Surgical, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted EPS of $2.53, which surpassed the Zacks Consensus Estimate by 12.4%. Revenues of $2.87 billion beat the Zacks Consensus Estimate by 4.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
ISRG has an estimated long-term earnings growth rate of 15.7% compared with the industry’s 12.7% growth. The company beat earnings estimates in each of the trailing four quarters, the average surprise being 13.24%.
Cardinal Health, carrying a Zacks Rank #2 (Buy) at present, posted a second-quarter fiscal 2026 adjusted EPS of $2.63, exceeding the Zacks Consensus Estimate by 10%. Revenues of $65.6 billion topped the Zacks Consensus Estimate by 0.9%.
CAH has a long-term earnings growth rate of 15% compared with the industry’s 9.6% growth. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 9.3%.
Align Technology, carrying a Zacks Rank #2 at present, posted a fourth-quarter 2025 adjusted EPS of $3.29, exceeding the Zacks Consensus Estimate by 10.1%. Revenues of $1.05 billion outperformed the Zacks Consensus Estimate by 5.3%.
ALGN has an estimated long-term earnings growth rate of 10.1% compared with the industry’s 9.5% growth. The company’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 6.16%.